Shire (NASDAQ:SHPG) had its price target lifted by B. Riley to $200.00 in a research report sent to investors on Thursday. They currently have a buy rating on the biopharmaceutical company’s stock.

A number of other brokerages also recently weighed in on SHPG. Piper Jaffray reiterated a hold rating on shares of Shire in a report on Wednesday, January 3rd. Cantor Fitzgerald set a $222.00 price target on Shire and gave the company a buy rating in a report on Wednesday, January 3rd. Zacks Investment Research downgraded Shire from a hold rating to a sell rating in a report on Monday, April 9th. Liberum Capital reiterated a hold rating on shares of Shire in a report on Wednesday, December 20th. Finally, Cowen set a $225.00 price target on Shire and gave the company a buy rating in a report on Friday, January 5th. One analyst has rated the stock with a sell rating, eight have given a hold rating and eleven have given a buy rating to the company’s stock. Shire currently has an average rating of Buy and a consensus price target of $204.64.

Shares of Shire stock opened at $164.37 on Thursday. The firm has a market cap of $49,961.08, a PE ratio of 10.85, a P/E/G ratio of 1.29 and a beta of 1.31. The company has a current ratio of 0.97, a quick ratio of 0.55 and a debt-to-equity ratio of 0.46. Shire has a 12-month low of $123.73 and a 12-month high of $192.15.

Shire (NASDAQ:SHPG) last issued its quarterly earnings results on Thursday, April 26th. The biopharmaceutical company reported $3.37 earnings per share for the quarter, missing analysts’ consensus estimates of $3.58 by ($0.21). Shire had a net margin of 28.17% and a return on equity of 14.19%. equities research analysts predict that Shire will post 15.21 EPS for the current fiscal year.

The company also recently announced a semiannual dividend, which will be paid on Tuesday, April 24th. Shareholders of record on Friday, March 9th will be paid a $0.8937 dividend. The ex-dividend date of this dividend is Thursday, March 8th. This represents a yield of 1.33%. This is an increase from Shire’s previous semiannual dividend of $0.15. Shire’s payout ratio is 6.93%.

Hedge funds and other institutional investors have recently modified their holdings of the business. Telemus Capital LLC purchased a new position in Shire in the fourth quarter valued at about $350,000. Snow Capital Management LP purchased a new position in Shire in the fourth quarter valued at about $33,891,000. FNY Partners Fund LP grew its stake in Shire by 346.6% in the fourth quarter. FNY Partners Fund LP now owns 474,460 shares of the biopharmaceutical company’s stock valued at $73,598,000 after purchasing an additional 368,214 shares in the last quarter. Boston Partners grew its stake in Shire by 60.9% in the fourth quarter. Boston Partners now owns 2,342,391 shares of the biopharmaceutical company’s stock valued at $363,351,000 after purchasing an additional 886,572 shares in the last quarter. Finally, Raymond James & Associates grew its stake in Shire by 15.5% in the fourth quarter. Raymond James & Associates now owns 101,051 shares of the biopharmaceutical company’s stock valued at $15,675,000 after purchasing an additional 13,567 shares in the last quarter. Hedge funds and other institutional investors own 19.58% of the company’s stock.

WARNING: This news story was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The original version of this news story can be read at https://www.thecerbatgem.com/2018/04/22/shire-shpg-price-target-raised-to-200-00-at-b-riley.html.

Shire Company Profile

Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells specialist medicines for people with rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.

Analyst Recommendations for Shire (NASDAQ:SHPG)

Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.